首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1917800

照護現場基因檢測市場－2026-2031年預測

Point-Of-Care Genetic Testing Market - Forecast from 2026 to 2031

出版日期: 2026年01月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2025 年，照護現場(POC) 基因檢測市場規模將達到 19.37 億美元，到 2031 年將達到 26.78 億美元，複合年成長率為 5.55%。

照護現場基因檢測（POC GT）市場是診斷和精準醫療領域一個變革性且快速成長的細分市場。其特點是在非集中式實驗室環境下進行基因分析，並在臨床相關的時限內，於患者所在位置或附近提供可操作的檢測結果。這種由可攜式整合平台實現的去中心化模式，透過大幅縮短檢測週期、簡化檢測流程以及將基因數據直接整合到即時臨床決策中，從根本上改變了基因診斷的範式。

主要市場促進因素和臨床需求

推動市場成長的關鍵因素之一是醫療模式轉向個人化和精準醫療的加速。隨著治療策略越來越依賴個體的基因譜，快速且方便的基因分型變得至關重要。即時基因檢測（POC基因檢測）滿足了這一需求，使醫生能夠在診療現場根據數據做出藥物選擇、劑量調整和治療方法分層等決策。這種能力在腫瘤學、藥物基因組學和感染疾病等領域尤其重要，因為及時獲得的基因資訊直接影響治療效果和患者預後。

另一個並行的驅動力是照護現場平臺本身的技術革新。微流體、生物感測器和分子診斷技術的進步融合，催生出既精密又易於使用的系統，能夠在分散式環境下執行複雜的基因分析，包括PCR、等溫擴增和靶向定序。這些系統將樣本製備、擴增和檢測整合到基於晶片的自動化工作流程中，最大限度地減少了人工操作時間和所需的專業技術。這種技術革新正將即時基因檢測從簡單的檢測概念轉變為能夠檢測多種具有重要臨床意義的基因標記的方法。

此外，臨床醫生和患者對遺傳學在健康和疾病中作用的認知不斷提高，也帶來了持續的需求。大眾對遺傳疾病的了解日益加深，加之醫師在基因組醫學方面的教育不斷進步，正推動人們積極進行風險評估、早期診斷和計劃生育的檢測。即時檢測（POC檢測）的固有優勢——便捷、快速、減少患者隨訪需求——與這一趨勢完美契合，促進了檢測的普及和融入日常診療實踐，尤其是在基層醫療和急診護理機構。

戰略優勢與價值提案

即時基因檢測的核心提案在於其快速出具結果和及時決策的能力。透過消除檢體運輸和中心檢查室批量處理帶來的物流延誤，診斷時間從數天或數週縮短至數分鐘或數小時。這種速度使得臨床能夠即時採取應對措施，例如啟動標靶治療、調整藥物和實施感染控制措施，從而顯著改善病患管理、提高醫院工作流程效率並降低整體醫療成本。在患者就診時獲取基因資訊也有助於提高醫療服務的連續性和患者滿意度。

區域市場動態

北美已確立其領先的區域市場地位，憑藉其先進的醫療基礎設施、精準醫療的高普及率、優惠的報銷機制以及對診斷創新的大量投資，保持著這一主導地位。主要平台開發商的存在和強大的生物技術產業進一步鞏固了其主導地位。然而，該市場正經歷全球擴張。歐洲和亞太等地區正經歷著加速成長，這得益於醫療現代化程度的提高、遺傳疾病盛行率的上升以及對分散式醫療模式投資的增加，表明即時基因檢測（POC GT）解決方案的地域部署範圍正在擴大。

競爭格局與平台演進

競爭格局主要由成熟的診斷公司和專業的分子診斷公司所構成。主要企業在檢測專案廣度、分析效能、易用性、速度以及與數位健康生態系統的連結性等方面競爭。市場以完全整合的盒式系統為主導，這些系統在感染疾病佔據主導地位，並正日益滲透到腫瘤學和藥物基因組學應用領域。策略重點在於擴展檢測範圍以涵蓋更多基因標靶，提升多重檢測能力，並確保平台在各種資源環境下可靠運作。展現明確的臨床效用、成本效益以及與各種臨床工作流程的無縫整合是成功的關鍵。

挑戰與未來前景

市場成長面臨許多挑戰，包括需要對分散式檢查進行嚴格的監管檢驗、確保非實驗室環境下的品管一致性，以及解決新型即時檢測（POC）的報銷政策問題。此外，平台和試劑盒的初始成本在成本敏感環境中也可能成為推廣應用的障礙。

然而，長遠發展方向無疑是擴展和完善。未來的成長將由技術的持續小型化、針對慢性病和腫瘤的新型生物標記組合的開發以及人工智慧在結果解讀中的應用所驅動。即時基因檢測與遠端醫療和數位健康記錄的融合將進一步鞏固其在構建診斷和治療之間持續、數據驅動的閉迴路中的作用。

總之，照護現場基因檢測市場正處於邁向即時、可操作的基因組分析的關鍵轉折點。其發展與精準醫療的進步和診斷能力的去中心化密不可分。對業內專家而言，策略挑戰在於開發一個強大的、符合CLIA豁免標準的平台，並擴展其臨床應用範圍；產生可靠的衛生經濟學證據；以及建立獲得監管部門核准和報銷的途徑。未來，即時基因檢測將成為貫穿整個醫療保健流程的綜合工具，從根本上提高醫療干預的速度和個人化程度。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The point-of-care genetic testing (POC GT) market is a transformative and rapidly expanding segment within the diagnostics and precision medicine landscape. It is defined by the execution of genetic analyses outside of centralized laboratory settings, providing actionable results at or near the patient location within a clinically relevant timeframe. This decentralization, enabled by portable and integrated platforms, is fundamentally altering the paradigm of genetic diagnostics by dramatically reducing turnaround times, simplifying testing workflows, and integrating genetic data directly into immediate clinical decision-making.

Core Market Drivers and Clinical Imperatives

The primary catalyst for market growth is the accelerating transition toward personalized and precision medicine. As therapeutic strategies become increasingly tailored to an individual's genetic profile, the need for rapid, accessible genotyping has become paramount. POC genetic testing fulfills this need by enabling clinicians to make data-driven decisions on drug selection, dosing, and therapy stratification at the point of clinical interaction. This capability is critical in fields like oncology, pharmacogenomics, and infectious disease, where timely genetic information directly impacts treatment efficacy and patient outcomes.

A concurrent driver is the expanding technical capabilities of point-of-care platforms themselves. Advances in microfluidics, biosensors, and molecular diagnostics have converged to create sophisticated, yet user-friendly, systems capable of performing complex genetic analyses-such as PCR, isothermal amplification, and targeted sequencing-in decentralized settings. These systems integrate sample preparation, amplification, and detection into automated, cartridge-based workflows, minimizing hands-on time and technical expertise required. This technological evolution is transforming POC GT from a concept for simple tests into a viable modality for a broadening range of clinically significant genetic markers.

Furthermore, growing clinical and patient awareness of the role of genetics in health and disease is creating sustained demand. Increased public understanding of hereditary conditions, coupled with physician education on genomic medicine, is driving proactive testing for risk assessment, early diagnosis, and family planning. The inherent advantages of POC testing-convenience, speed, and reduced need for patient follow-up-align perfectly with this trend, facilitating higher testing uptake and integration into routine care pathways, particularly in primary and acute care settings.

Strategic Advantages and Value Proposition

The definitive value proposition of POC genetic testing lies in its capacity for rapid results and timely decision-making. By eliminating the logistical delays associated with sample transport and batch processing in core labs, it compresses the diagnostic timeline from days or weeks to minutes or hours. This acceleration enables immediate clinical actions, such as initiating targeted therapy, adjusting medication, or implementing infection control measures, which can significantly improve patient management, streamline hospital workflows, and reduce overall healthcare costs. The ability to obtain genetic information during a single patient visit also enhances care continuity and patient satisfaction.

Geographic Market Dynamics

North America is established as the leading regional market, a position sustained by a synergistic combination of advanced healthcare infrastructure, high adoption of precision medicine, favorable reimbursement frameworks, and significant investment in diagnostic innovation. The presence of major platform developers and a robust biotech sector further consolidates this leadership. However, the market is experiencing global expansion. Regions such as Europe and Asia-Pacific are witnessing accelerated growth driven by increasing healthcare modernization, rising prevalence of genetic disorders, and growing investment in decentralized care models, indicating a broadening geographic footprint for POC GT solutions.

Competitive Landscape and Platform Evolution

The competitive environment is characterized by established diagnostic corporations and specialized molecular companies. Leaders compete on the basis of test menu breadth, analytical performance, ease of use, speed, and connectivity within digital health ecosystems. The market features fully integrated, cartridge-based systems that dominate the infectious disease segment and are increasingly penetrating oncology and pharmacogenomic applications. Strategic focus is on expanding test panels to cover more genetic targets, improving multiplexing capabilities, and ensuring platforms can operate reliably in varied resource settings. Success depends on demonstrating clear clinical utility, cost-effectiveness, and seamless integration into diverse clinical workflows.

Challenges and Future Trajectory

Market growth faces challenges, including the need for stringent regulatory validation of decentralized tests, ensuring consistent quality control outside the lab environment, and navigating reimbursement policies for novel POC assays. The initial cost of platforms and cartridges can also be a barrier to widespread adoption in cost-sensitive settings.

Nevertheless, the long-term trajectory is unequivocally toward expansion and sophistication. Future growth will be driven by the continuous miniaturization of technology, the development of new biomarker panels for chronic disease and oncology, and the integration of artificial intelligence for result interpretation. The convergence of POC genetic testing with telehealth and digital health records will further solidify its role in creating a continuous, data-driven loop between diagnosis and treatment.

In conclusion, the point-of-care genetic testing market represents a pivotal shift toward immediate, actionable genomics. Its evolution is inextricably linked to the advancement of precision medicine and the decentralization of diagnostic capabilities. For industry experts, the strategic imperative lies in developing robust, CLIA-waived platforms with expanding clinical menus, generating robust health-economic evidence, and navigating the pathway to regulatory approval and reimbursement. The future points toward POC genetic testing becoming an embedded tool across the care continuum, fundamentally enhancing the speed and personalization of medical intervention.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Point-of-Care Genetic Testing Market Segmentation

By Type
Polymerase Chain Reaction (PCR)
Isothermal Amplification
Others
By Application
Infectious Disease
Cancer Screening
Personalized Medicine
Others
By End-User
Hospitals
Specialized Clinics
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. POINT-OF-CARE GENETIC TESTING MARKET BY TYPE

5.1. Introduction
5.2. Polymerase Chain Reaction (PCR)
5.3. Isothermal Amplification
5.4. Others

6. POINT-OF-CARE GENETIC TESTING MARKET BY APPLICATION

6.1. Introduction
6.2. Infectious Disease
6.3. Cancer Screening
6.4. Personalized Medicine
6.5. Others

7. POINT-OF-CARE GENETIC TESTING MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Specialized Clinics
7.4. Others

8. POINT-OF-CARE GENETIC TESTING MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others